glp 1 comorbidities Long-term Success of GLP-1s Hinges on More Than Just a Prescription GLP-1 Receptor Agonist Market Growth

In fact, in one long-term commitment

Cell 166 , 209221 (2016)

These medications slow gastric emptying to improve blood sugar control and promote weight loss, but this same mechanism may contribute to reflux symptoms

While ALD and MASLD were historically viewed as distinct entities, they share similar histology and some pathological mechanisms, most notably altered metabolic homeostasis in the liver and adipose tissue

The global market for GLP-1 receptor agonists was valued at USD 53.46 billion in 2024 and is expected to grow to USD 156.71 billion by 2030 , reflecting a compound annual growth rate of 17.46% between 2025 and 2030